Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Our RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Our toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, we are leading the charge toward a world in which human potential is no longer hindered by the burden of disease.
Wave Life Sciences的外部链接
Join our Chief Development Officer, Anne-Marie Li-Kwai-Cheung, for a Jett Foundation discussion on FORWARD-53, our WVE-N531 clinical trial in boys with #Duchenne muscular dystrophy amenable to exon 53 skipping.
??? We invite you to tune in to our Community Webinar Series on December 5 to hear from Anne-Marie Li-Kwai-Cheung on Wave Life Sciences' WVE-N531 overview and interim clinical trial results. Register for free at https://lnkd.in/ejvur23n.
This week in observance of #Alpha1Awareness month, Dan, living with #Alpha1, joined us on campus. After his diagnosis at 61 years old, Dan stepped into the role of being his own advocate while also providing a source for comfort and support of others in their Alpha-1 journey. Thank you, Dan, for all you do for the Alpha-1 Foundation and for inspiring all of us at Wave.
Today we announced our 3Q 2024 results and provided updates across our diverse portfolio of innovative #RNA medicines, including our lead programs in #HuntingtonsDisease, #AATD, #Duchenne & #obesity, as well as our emerging #RNAediting programs in cardiometabolic diseases. Read more and watch the webcast: https://lnkd.in/en4-55uE
Our team’s commitment to patient communities transcends the lab. When Anna R. Smith, Ph.D. joined Wave, she was already integrated in the Alpha-1 antitrypsin deficiency?community, fresh off a successful dissertation focused on #AATD. Her commitment to the #Alpha1 community was seen first-hand at Alpha-1 Foundation’s annual Escape to the Cape bike trek in September, where she took a 150-mile journey to raise awareness and show support for Alpha 1 families. Learn more about Anna’s background and why she joined Wave. #Alpha1Awareness #Alpha1RidingforAReason #Alpha1AwarenessMonth #WeAreWave
We are honored to host the Boston Area Pharmaceutical Toxicology Group (BAPTG) at our Lexington, MA facility! Colleagues from across the oligonucleotide field will be discussing opportunities and challenges in the development of #RNA therapeutics, with a specific focus on toxicology, pathology, and safety risk assessment. Learn more about BAPTG here: baptg.org.
#DYK: over 90% of people with #Alpha1 are believed to be underdiagnosed? During #Alpha1Awareness Month, learn more about this genetic disease from Alpha-1 Foundation: https://lnkd.in/gKMhjiKp #AATD
此处无法显示此内容
在领英 APP 中访问此内容等
Every year our Research Day is an opportunity to highlight the latest advancements in #oligonucleotide chemistry being made by Wave, and how those advancements are translating into novel therapeutic approaches. Watch the replay: https://lnkd.in/eFjHr5pv #ReimaginePossible
Today during our annual Research Day, we shared updates on our growing pipeline including our INHBE siRNA program for #obesity and new #RNAediting programs. Watch the replay and learn more here: https://lnkd.in/eP4R4pj5
Each quarter, employees are recognized for their achievements and contributions to Wave -- we call these Swell Awards. ?? We’re proud of our third quarter winners for their collaboration within the organization to advance our goals and their commitment to #ReimaginePossible for RNA medicines?and?for patients!?Congratulations?Jianxin Gao, Elizabeth Wagner, Marina Petrillo, Snehlata Tripathi, Shushi Kabu and Joseph Foley. We're proud to have you on our team! #WeAreWave
Join us October 30th for our annual Research Day. We’ll be presenting on our rapidly advancing, wholly owned pipeline of RNA medicines, including new #RNAediting programs and preclinical data for our WVE-007 INHBE program for #obesity. Learn more and register today: https://lnkd.in/gg8nXcgF